Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Mahaffey

Showing results (11-20 of 635) with videos related to

Pageof 64
Sort By:
European Heart Journal|June 15, 2013
Atrial fibrillation: a spectrum of risk with a uniform treatment effect of novel anticoagulants?Kenneth W Mahaffey, Robert M Califf
European Heart Journal|June 7, 2018
Initiating anticoagulation with the intention of cardioverting: does drug choice matter?Kenneth W Mahaffey, Mintu P Turakhia
Journal of Interventional Cardiology|June 18, 2002
Experience with glycoprotein IIb/IIIa antagonists in patients with acute coronary syndromesDavid E Kandzari, Kenneth W Mahaffey
Future Cardiology|February 19, 2020
Cangrelor in clinical useKent Y Feng, Kenneth W Mahaffey
JAMA|February 15, 2007
Optimal timing for use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: questions, answers, and more questionsKenneth W Mahaffey, Robert A Harrington
Circulation|November 30, 2006
The scientific community's quest to identify optimal targets for anticoagulant pharmacotherapyKenneth W Mahaffey, Richard C Becker
Current Cardiology Reports|December 14, 2011
Promises of PAR-1 inhibition in acute coronary syndromeSergio Leonardi, Pierluigi Tricoci, Kenneth W Mahaffey
Coronary Artery Disease|July 12, 2016
Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibitionLeo Ungar, Fatima Rodriguez, Kenneth W Mahaffey
The New England Journal of Medicine|September 12, 2019
Canagliflozin and Renal Outcomes in Diabetic Nephropathy. ReplyMeg J Jardine, Kenneth W Mahaffey, Vlado Perkovic
Circulation|October 26, 2018
Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist"David R Matthews, Vlado Perkovic, Kenneth W Mahaffey
Pageof 64

Showing results (11-20 of 635) with videos related to

Sort By:
Pageof 64
European Heart Journal|June 15, 2013
Atrial fibrillation: a spectrum of risk with a uniform treatment effect of novel anticoagulants?Kenneth W Mahaffey, Robert M Califf
European Heart Journal|June 7, 2018
Initiating anticoagulation with the intention of cardioverting: does drug choice matter?Kenneth W Mahaffey, Mintu P Turakhia
Journal of Interventional Cardiology|June 18, 2002
Experience with glycoprotein IIb/IIIa antagonists in patients with acute coronary syndromesDavid E Kandzari, Kenneth W Mahaffey
Future Cardiology|February 19, 2020
Cangrelor in clinical useKent Y Feng, Kenneth W Mahaffey
JAMA|February 15, 2007
Optimal timing for use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: questions, answers, and more questionsKenneth W Mahaffey, Robert A Harrington
Circulation|November 30, 2006
The scientific community's quest to identify optimal targets for anticoagulant pharmacotherapyKenneth W Mahaffey, Richard C Becker
Current Cardiology Reports|December 14, 2011
Promises of PAR-1 inhibition in acute coronary syndromeSergio Leonardi, Pierluigi Tricoci, Kenneth W Mahaffey
Coronary Artery Disease|July 12, 2016
Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibitionLeo Ungar, Fatima Rodriguez, Kenneth W Mahaffey
The New England Journal of Medicine|September 12, 2019
Canagliflozin and Renal Outcomes in Diabetic Nephropathy. ReplyMeg J Jardine, Kenneth W Mahaffey, Vlado Perkovic
Circulation|October 26, 2018
Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist"David R Matthews, Vlado Perkovic, Kenneth W Mahaffey
Pageof 64